Tikva Allocell Announces Exclusive Licensing of Cell Therapy Technologies from Baylor College of Medicine

Tikva announces exclusive licensing of novel cell therapy technologies from Baylor College of Medicine to progress its pipeline of promising cell therapies against solid tumors.

SINGAPORE – 12 Mar 2024 – Tikva Allocell Pte Ltd (“Tikva” or the “Company”), a preclinical ‘off-the-shelf’ cell therapy company targeting solid tumors announces exclusive licensing of novel cell therapy technologies from Baylor College of Medicine (“BCM”) to progress its pipeline of promising cell therapies against solid tumors. The agreement with BCM offers the Company exclusive global rights to the use of modified allogeneic Virus Specific T Cell (VST) products and other innovative strategies for the treatment of solid tumors.

Tikva’s allogeneic cell therapy platform is based on decades of research at BCM by Dr. Malcolm Brenner, Dr. Cliona Rooney and Dr. Helen Heslop, who have co-founded the Company with Dr. Ivan Horak – a cancer therapy expert with extensive leadership experience in the global pharmaceutical industry. Dr. Brenner and Dr. Heslop are elected members of the National Academy of Medicine and all three co-founders will serve as scientific advisors of the Company. The VST platform has clinically proven safety in the allogeneic setting. Combined with Tikva’s proprietary protein engineering strategies, the Company’s cell therapies are well positioned to overcome key off-the-shelf therapy challenges like cell persistence and durability.

Founder and Chief Executive Officer Dr. Ivan Horak stated, “The Center for Cell and Gene Therapy at Baylor College of Medicine has deep expertise in developing novel immune-oncology therapies through basic and clinical research. Our work with the BCM team will further propel Tikva’s efforts in bringing innovative, safe and efficacious cell therapies to the clinic for the benefit of cancer patients with unmet medical needs.”

Co-Founder and Scientific Advisor Dr. Cliona Rooney indicated, “Virus Specific Cells have unique properties that make them an advantageous platform for off-the-shelf cell therapies with the potential to effectively target solid malignancies with minimal safety risks such as Graft versus Host Disease. We look forward to working closely with Tikva Allocell to bring these promising innovative cell therapies to the clinic.”

About Tikva Allocell

Tikva Allocell Pte Ltd is a preclinical stage biotech company headquartered in Singapore. Our cell therapy platform is an off-the-shelf CAR-T therapy, utilizing allogeneic T cells prepared from the blood of Epstein-Barr virus (EBV) positive healthy individuals. Our approach exploits the intrinsic properties of virus specific T cells (VSTs), enhanced by IP protected novel repurposing strategies to enhance cell performance and safely target patients with solid tumors including gastric, prostate and triple negative breast cancers.

For more information on Tikva, please visit www.tikvaallocell.com.

Investors and Media Contact

Wilson W. Cheung

CHIEF FINANCIAL OFFICER
Share the Post:

Related Posts